These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35579744)

  • 1. Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer.
    Wei B; Shan Y; Du Z; Yin C; Zhang Q; Lin H; Zhang G; Song D; Zuo H
    Appl Biochem Biotechnol; 2022 Sep; 194(9):3961-3973. PubMed ID: 35579744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
    Zhou Y; Xu Y; Wang C; Gong Y; Zhang Y; Yao R; Li P; Zhu X; Bai J; Guan Y; Xia X; Yang L; Yi X; Sun Q
    Breast Cancer Res Treat; 2021 Aug; 188(3):661-673. PubMed ID: 34003409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Potential Predictive Biomarker for Miller/Payne Grading: PD-L1 Expression before Neoadjuvant Chemotherapy in Breast Cancer.
    Li C; Ma RZ; Han GY; Guo YH; Zhang YN; Zhang YT; Wang H; Zhang YP; Chen FM; Zhang SG; Wang MC; Hao FR; Zhang YX
    Oncol Res Treat; 2020; 43(11):573-583. PubMed ID: 32957100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
    Zhang M; Yang H; Fu T; Meng M; Feng Y; Qu C; Li Z; Xing X; Li W; Ye M; Li S; Bu Z; Jia S
    Mol Oncol; 2023 Sep; 17(9):1930-1942. PubMed ID: 37356061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
    Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
    BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast enhanced ultrasound quantitative parameters for assessing neoadjuvant chemotherapy response in patients with locally advanced breast cancer.
    Sharma A; Grover SB; Mani C; Ahluwalia C
    Br J Radiol; 2021 May; 94(1121):20201160. PubMed ID: 33860674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
    Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
    Kim H; Kim YJ; Park D; Park WY; Choi DH; Park W; Cho WK; Kim N
    Breast Cancer Res Treat; 2021 Aug; 189(1):167-175. PubMed ID: 34152505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
    Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M
    Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Analysis of Disseminated Tumor Cells (DTCs) and Circulating Tumor DNA (ctDNA) in a Patient Suffering from Triple Negative Breast Cancer Revealed Elevated Risk.
    Nel I; Herzog H; Aktas B
    Front Biosci (Landmark Ed); 2022 Jun; 27(7):208. PubMed ID: 35866394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
    Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
    EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.
    Romero A; García-Sáenz JA; Fuentes-Ferrer M; López Garcia-Asenjo JA; Furió V; Román JM; Moreno A; de la Hoya M; Díaz-Rubio E; Martín M; Caldés T
    Ann Oncol; 2013 Mar; 24(3):655-61. PubMed ID: 23104719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer.
    Wang K; Chai J; Xu J; Wei J; Li P; Liu Y; Ma J; Xu T; Zhao D; Yu K; Fan L; Yan Q; Guo S; Li M; Wang Z
    Pathol Res Pract; 2021 Oct; 226():153603. PubMed ID: 34500374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
    Singh LC; Chakraborty A; Mishra AK; Devi TR; Sugandhi N; Chintamani C; Bhatnagar D; Kapur S; Saxena S
    Med Oncol; 2012 Jun; 29(2):539-46. PubMed ID: 21528410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems (CSBrS-026).
    Xiang H; Xin L; Ye J; Xu L; Zhang H; Zhang S; Liu Y
    Chin J Cancer Res; 2023 Dec; 35(6):702-712. PubMed ID: 38204446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
    Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
    Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Gan FJ; Li Y; Xu MX; Zhou T; Wu S; Hu K; Li Y; Sun SH; Luo Q
    Cancer Biomark; 2021; 32(3):339-351. PubMed ID: 34151842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.